---
title: "At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus… — Lilly — DecisionGateway"
description: "statement by Lilly, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e"
meta:
  "og:description": "statement by Lilly, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus… — Lilly — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.**

A statement by Lilly. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.*

pattystraphousePublished 2026-11-09 [ Read source](https://t.me/pattystraphouse/1264)

## **Discussion**

## **Related claims**

[**Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.**Eli Lilly · statement](https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0) [**The high placebo response rate is because all patients received 600mg high dose for 16 weeks in Period 1, not because of a large placebo effect; 75% of the placebo group maintained ACR20 through week 28.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db45-7c00-9e32-c82440862863) [**This widens Foundayo's commercial lane beyond weight loss alone.**MY READ · prediction](https://dgw.tmarket.io/claims/01a1de6e-5112-7882-bd64-d12955f147d6) [**If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.**MY READ · prediction](https://dgw.tmarket.io/claims/01a1de6e-5122-756f-a303-e5ee7c04cfd4) [**Four-week averages were between 2% and 2.3%.**post author · statement](https://dgw.tmarket.io/claims/01a1db7c-67ed-7805-8651-a3f6e3278211) [**The October NFP came in extremely weak last month.**post author · statement](https://dgw.tmarket.io/claims/01a1de0e-8f69-7965-b40b-79c3460142dc)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,500+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e#webpage","@type":"WebPage","description":"statement by Lilly, recorded recently — verbatim quote and source citation.","name":"At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus… — Lilly — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"At 52 weeks, the apnea-hypopnea index fell by an average…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-09","isBasedOn":"https://t.me/pattystraphouse/1264","text":"At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.","url":"/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
